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Numbers of cases (with equal number of controls) required to
achieve 80% power at a significance level of 0.05 for a range of
odds ratios and three inheritance models. Estimates are based
on a risk allele frequency of 0.20 and a population risk of osteo-
arthritis of 5%
Odds ratio Inheritance model
Recessive Dominant Multiplicative
1.10 43276 7418 5269
1.15 19766 3434 2425
1.20 11419 2010 1411
1.25 7500 1338 934Geneticists are beside themselves with excitement now that
they know that genome-wide association scans (GWASs)
work. The latest breakthroughs, exempliﬁed by the Well-
come Trust Case Control Consortium (WTCCC), are uncov-
ering a number of novel susceptibility loci for many
common, complex diseases1. New insights into disease
pathways are emerging and the successes have been
such that the Wellcome Trust is now encouraging groups
with other large disease cohorts to bid for GWAS funding.
Osteoarthritis has entered the GWAS arena with gusto,
with a number of projects underway or about to begin. These
include studies in Europe, Asia and North America and in-
clude arcOGEN, a project funded by the Arthritis Research
Campaign in the UK, and TREAT-OA, an European-wide
project funded by the European Commission and directed
towards association and functional analysis of osteoarthritis
susceptibility loci.
What characterises the GWAS projects is their use of rel-
atively large cohorts of cases and controls, with the mini-
mum number of cases being in the thousands. The
reason for this is that the vast majority of complex trait
loci individually contribute only a fraction to the overall her-
itability of the disease under study, with large numbers of
cases and controls being required to conﬁdently detect
these weak effects and to also account for the large number
of polymorphisms genotyped. Geneticists now realise that
strong genetic effects, as seen for example by polymor-
phism at the HLA locus in many autoimmune diseases,
are the exception rather than the rule. Since the vast major-
ity of complex trait loci have odds ratios <1.5, there is little
merit in performing association analyses on caseecontrol
cohorts that number only a few hundred individuals, since
the most likely positive outcome from such studies is a false
one (Table I). Why then do some investigators in the oste-
oarthritis ﬁeld persist in studying small cohorts in their ge-
netic association studies and why are such reports still
being published? We assume that not everyone is yet
aware of the importance of genotyping large cohorts and
we hope that this editorial will encourage them to read the
latest literature and to move towards the use of adequately
powered studies.
We accept that there could be instances in which investi-
gators have decided to study a very discrete, and conse-
quently rare, phenotype that they hypothesise may have*Address correspondence and reprint requests to: Dr J.
Loughlin, Ph.D., University of Oxford, Institute of Musculoskeletal
Sciences, Botnar Research Centre, OX3 7LD, Oxford, UK;
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277a unique genetic architecture. If this is their belief then the
onus must be on the investigators to justify it. Our experi-
ence is that most osteoarthritis association studies involve
cases ascertained using standard radiographic assessment
or surgical outcomes. In these instances there is little ex-
cuse for small cohorts since most osteoarthritis cases are
eligible for study recruitment under at least one of these
two criteria.
It can be argued that meta-analysis is a mechanism to
deal with the plethora of small studies. There is no doubt
that meta-analysis is an extremely useful tool but it, like
other statistical methods, works best when the input data
are sound. Why feed it gruel when a nutritious diet of ade-
quately powered studies would enable an accurate and re-
liable assessment to be made of the contribution that
a polymorphism makes to disease susceptibility?
When reviewing reports of positive genetic associations
derived from small cohorts there is a recurring question: if
the investigators think it likely that they may well have un-
covered a true association then surely they are keen to ge-
notype the polymorphism in a larger cohort to be certain of
their ﬁnd? If the association is real, then replication and
a good publication is likely to follow and if it is a false pos-
itive, then the authors will have saved themselves and
others in the ﬁeld from unnecessarily pursuing the locus fur-
ther. In many instances, however, there appears to be no
obvious attempt by the original investigators to try and rep-
licate the ﬁnd. For such a common disease as osteoarthritis
this is unacceptable.1.30 5342 965 670
1.35 4023 736 509
1.40 3156 584 402
1.45 2553 478 328
1.50 2117 401 274
278 J. Loughlin and K. Chapman: Big is beautifulWe believe that the insights into association analysis that
have come from the powerful association studies must be
taken on board by the osteoarthritis research community,
and that the geneticists amongst us who ply our trade in
this particular disease area must strive to carry out the
most robust and powerful studies that we reasonably can.
With a common disease such as osteoarthritis there is no
justiﬁcation for performing association studies on casee
control cohorts of small sizes unless a genuine and rare
sub-phenotype is being examined. Investigators should be
determined to collect large cohorts and manuscript re-
viewers and journal editors should demand large sample
sizes for genetic association reports. For candidateegene
association analyses we propose minimum case sample
sizes of 500 and minimum control sample sizes also of
500. Replication should then be sought, with a willingnessof other investigators to offer access to their cohorts. Gen-
otyping costs are decreasing at a rate that makes such col-
laboration affordable. If replication is obtained, and this may
require a meta-analysis, only then should publication be
sought.
Tough measures now will pay huge dividends down-
stream and will ensure that false leads are not followed
and that enough large caseecontrol cohorts are available
globally to fully elucidate the genetic architecture of this
common, complex arthritis.Reference
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